Dec. 11 at 7:55 PM
$IMRN will be interesting to see the detailed analysis of the study and why it either showed less magnitude of effect or potentially wasn’t powered correctly. Soldiers given diarrhea pills without great guidance would have still likely began to eagerly take the med when they didn’t take it initially and became symptomatic, so this may still be a great study for secondary endpoint (clearance) analysis, assuming it wasn’t a total botch. I won’t be in a rush to do anything until detailed analysis and end of ph2 updates are given in coming weeks. Will also want to hear detailed discussion from company on reasons why they felt the non-IND study wasn’t reflective of drug (aside from stark contrast to all other data on the compound), as there could also be a surprise there. Added a bit, as the sudden lack of volatility also suggests manipulation, can always add more if we see a sub 1 day, but this likely isn’t a short to zero type of stock, given the dual exchange setup and govt contracts
